Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488087 | SCV000574835 | uncertain significance | not provided | 2017-01-01 | criteria provided, single submitter | clinical testing | |
Department of Otolaryngology – Head & Neck Surgery, |
RCV001375342 | SCV001572060 | uncertain significance | Hearing impairment | 2021-04-12 | criteria provided, single submitter | clinical testing | PP3_Supporting, BS2_Strong |
Fulgent Genetics, |
RCV002496880 | SCV002791348 | likely benign | Hypoparathyroidism, deafness, renal disease syndrome | 2024-03-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000488087 | SCV003520428 | uncertain significance | not provided | 2023-09-01 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs750735308, gnomAD 0.009%). This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 120 of the GATA3 protein (p.Thr120Met). This variant has not been reported in the literature in individuals affected with GATA3-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GATA3 protein function. ClinVar contains an entry for this variant (Variation ID: 424946). |